Doximity GPT vs OpenEvidence
The two products a United States clinician can use free today, reached through very different front doors. Doximity's assistant lives inside the professional network the company has operated since 2010, and its most distinctive design decision is one nobody else in this category states: an explicit internal boundary between where the product retrieves and where it generates, so drug answers come from a quantified corpus rather than from the model. OpenEvidence has the stronger evidence position by a wide margin, with eleven independent studies evaluating it in two years and named partnerships with the New England Journal of Medicine, JAMA and Cochrane, plus Epic embedding at named health systems. Doximity has published no evaluation of the assistant at all. Both are free because a pharmaceutical company is paying somewhere in the chain, and the difference is only where.
- The architecture is stated in the useful way: the company draws an explicit line inside its own product between where it retrieves and where it generates, with the drug corpus quantified, so a clinician knows which answers are looked up and which are written.
- It sits inside a professional network the company has run since 2010, so access for a verified United States clinician is close to frictionless and the same account already carries the rest of the toolset.
- The data commitments are specific rather than decorative: encryption in transit and at rest, and sessions stated to be private to the individual clinician.
- Eleven independent studies published between 2024 and 2026 evaluating this product, identified through a systematic review following PRISMA, against a product with no located evaluation of any kind.
- Named content partnerships rather than an unspecified corpus: the New England Journal of Medicine, JAMA and its eleven specialty journals, and Cochrane Systematic Reviews.
- It reaches the record system. Enterprise deployment is embedded in Epic and documented at Mount Sinai across seven hospitals, where no electronic health record integration was located for the alternative.
Side by Side
| Axis | D Doximity GPT |
O OpenEvidence |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The business models differ in ways worth stating plainly. OpenEvidence is funded by pharmaceutical and medical device advertising displayed alongside clinical answers, governed by a published advertising policy that is the artifact to read before accepting the arrangement.
Doximity's products are funded by pharmaceutical marketing across the wider network rather than inside this assistant specifically, which is a different placement of the same commercial relationship and equally worth understanding. Doximity GPT publishes no accuracy study, error rate, clinician review panel or benchmark result, no governance artifact and no record system integration, and its naming is inconsistent across the company's own material. Neither product publishes a bias or subgroup performance analysis.